Cerebral Protection System Market size was valued at USD 726.5 Million in 2021 and is poised to grow at a significant CAGR of 9.2% over 2022–2028. The main treatment option for severe aortic stenosis that cannot be operated on or present a high surgical risk is transcatheter aortic valve implantation (TAVI). According to diffusion-weighted MRI research, certain silent brain infarcts develop following TAVI and cause subsequent mental decline. During TAVI, embolic protection devices provide a mechanical barrier against the debris that can induce brain embolization. The risk of cerebrovascular events associated with TAVI has decreased because of these devices. The market is growing due to an increase in the geriatric population, adoption of cutting-edge surgical procedures, and investments in health care. Technological development in embolic protection devices will contribute to corporate growth in a beneficial way. Technological developments that resulted in the creation of enhanced embolic protection devices for TAVI like CLEAN-TAVI offer a variety of prospects for the market’s expansion. The market will grow if companies concentrate on creating new and cost-effective technologies for instance, the double-occlusion balloon system in Medtronic’s Mo. Ma Ultra proximal cerebral protection device ensures proximal embolic protection before crossing a carotid lesion. The market for cerebral protection devices will expand due to the development of these products. Furthermore, favorable reimbursement policies for these systems will boost business growth by increasing usage.
Recent Market Developments:
In March 2020, The TriGUARD 3 TM Cerebral Embolic Protection (CEP) Device has received European CE Mark from Keystone Heart Ltd., a Venus MedTech Company. During Transcatheter Aortic Valve Implantation (TAVI) and other transcatheter cardiac procedures, the device is meant to divert embolic material away from cerebral circulation, reducing the risk of brain injury.
The TriGUARD 3TM Cerebral Embolic Protection Device was used for the first time in a commercial case in the world, according to Keystone Heart, a Venus MedTech company.
For $300 million, Venus MedTech (Hangzhou) Inc. bought a 100 percent stock interest and corresponding equity in Cardio valve Ltd. Cardio valve, established in Yehuda, Israel, makes the Cardio valve system, which is a transcatheter interventional replacement solution for mitral or tricuspid regurgitation.